Purple Biotech director reveals major equity stake

PURPLE BIOTECH LTD. director Shai S. Lankry filed an initial ownership report showing a sizable equity position.

Accepted by SEC EDGAR 03/27/2026 - 11:38 AM EDT

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

PURPLE BIOTECH LTD. director Shai S. Lankry filed an initial ownership report showing a sizable equity position. He holds 3,550,000 Ordinary Shares, including 3,254,167 unvested restricted stock units that settle in shares or ADSs. He also holds stock options to purchase 3,000,000 Ordinary Shares at an exercise price of $0.01359375 per share and options to purchase 3,550,000 Ordinary Shares at $0.00309375 per share, both vesting over several years and expiring in 2030.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Lankry Shai S

Role Director

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Stock Option (Right to Buy)	--	--	--
Holding	Ordinary Shares	--	--	--

Holdings: Stock Option (Right to Buy) — 6,550,000 contracts (Direct); Ordinary Shares — 3,550,000 shares (Direct)

Footnotes (3)

F1. Includes 3,254,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares
F2. Represents stock option to purchase 3,000,000 Ordinary Shares (equivalent to 1,500 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The options to purchase 1,000,000 Ordinary Shares will vest on April 29, 2026, with the remaining 2,000,000 Ordinary Shares vesting in equal quarterly installments until April 29, 2028. The exercise price of this stock option is $0.01359375 per Ordinary Share and the option expires on April 29, 2030.
F3. Represents stock option to purchase 3,550,000 Ordinary Shares (equivalent to 1,775 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 295,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 3,254,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for PURPLE BIOTECH (PPBT) disclose about Shai S. Lankry?

The filing shows director Shai S. Lankry’s initial equity holdings in Purple Biotech. It details Ordinary Shares, unvested restricted stock units, and substantial stock option positions with specific exercise prices, vesting schedules, and expiration dates under the company’s 2016 Equity-Based Incentive Plan.

How many unvested RSUs does Shai S. Lankry hold in PURPLE BIOTECH (PPBT)?

Shai S. Lankry holds 3,254,167 unvested restricted stock units in Purple Biotech. Each RSU represents one Ordinary Share, subject to time-based vesting, and is settled in Ordinary Shares, which may be represented by American Depositary Shares according to the disclosure footnotes.

What stock option grants are reported for Shai S. Lankry at PURPLE BIOTECH (PPBT)?

He has stock options to purchase 3,000,000 Ordinary Shares and separate options to purchase 3,550,000 Ordinary Shares. These options were issued under the 2016 Equity-Based Incentive Plan with detailed vesting schedules, exercise prices, and expiration dates extending to April and October 2030.

What are the exercise prices of Shai S. Lankry’s PURPLE BIOTECH (PPBT) stock options?

One option grant carries an exercise price of $0.01359375 per Ordinary Share, while another has an exercise price of $0.00309375 per Ordinary Share. Both sets of options relate to Ordinary Shares issued under Purple Biotech’s 2016 Equity-Based Incentive Plan.

When do Shai S. Lankry’s PURPLE BIOTECH (PPBT) stock options expire?

The 3,000,000-share stock option grant expires on April 29, 2030, while the 3,550,000-share option grant expires on October 21, 2030. Both grants have multi-year vesting schedules, with portions vesting in quarterly installments through those expiration dates.

How many of Shai S. Lankry’s PURPLE BIOTECH (PPBT) options are already vested?

For the 3,550,000-share option grant, options to purchase 295,833 Ordinary Shares are vested and exercisable. The remaining options to purchase 3,254,167 Ordinary Shares vest in equal quarterly installments until October 21, 2028, according to the Form 3 footnote disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lankry Shai S

(Last)

(First)

(Middle)

4 OPPENHEIMER STREET

(Street)

SCIENCE PARK, REHOVOT

7670104

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PURPLE BIOTECH LTD. [ PPBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	3,550,000⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	⁽²⁾	Ordinary Shares	3,000,000	⁽²⁾	D
Stock Option (Right to Buy)	⁽³⁾	⁽³⁾	Ordinary Shares	3,550,000	⁽³⁾	D

Explanation of Responses:

1. Includes 3,254,167 unvested restricted stock units ("RSUs"), each with respect to one ordinary share, no par value, per share ("Ordinary Shares"), of Purple Biotech Ltd. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares

2. Represents stock option to purchase 3,000,000 Ordinary Shares (equivalent to 1,500 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. The options to purchase 1,000,000 Ordinary Shares will vest on April 29, 2026, with the remaining 2,000,000 Ordinary Shares vesting in equal quarterly installments until April 29, 2028. The exercise price of this stock option is $0.01359375 per Ordinary Share and the option expires on April 29, 2030.

3. Represents stock option to purchase 3,550,000 Ordinary Shares (equivalent to 1,775 ADSs), issued to the reporting person pursuant to the Issuer's 2016 Equity-Based Incentive Plan. Options to purchase 295,833 Ordinary Shares are vested and exercisable, with the remaining options to purchase 3,254,167 Ordinary Shares vesting in equal quarterly installments until October 21, 2028. The exercise price of this stock option is $0.00309375 per Ordinary Share and the option expires on October 21, 2030.

	/s/ Shai Lankry	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR